Stockscreener 앱 받기
37.50
2.53%
0.9672
전일 마감가:
$36.53
열려 있는:
$37.82
하루 거래량:
437.40K
Relative Volume:
0.55
시가총액:
$761.97M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-25.68
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
-0.60%
1개월 성능:
-15.76%
6개월 성능:
+49.82%
1년 성능:
+4,087%
1일 변동 폭
$37.29
$39.75
1주일 범위
$35.02
$39.75
52주 변동 폭
$0.432
$66.92
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
37.46 | 743.08M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.02 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.49 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.63 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.79 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.67 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-26 | 개시 | Citigroup | Buy |
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Emerald Mutual Fund Advisers Trust Invests $13.27 Million in Nektar Therapeutics $NKTR - MarketBeat
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $137,935.89 in Stock - MarketBeat
Nektar Therapeutics’ chief R&D officer sells $137,935 in stock - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar TherapeuticsNKTR - PR Newswire
Emerald Advisers LLC Takes Position in Nektar Therapeutics $NKTR - MarketBeat
NK Cell Therapy Market 2034: 7MM Outlook, 30+ Active Developers, IND/NDA Momentum, and Next-Gen CAR-NK Innovations Driving Immunotherapy Advances | DelveInsight - Barchart.com
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
What Recent Price Target Signals For The Evolving Nektar Therapeutics (NKTR) Story - Yahoo Finance
Nektar Therapeutics: Share Price Dislocation Masks Rezpeg’s Underappreciated Atopic Dermatitis and Alopecia Areata Upside - TipRanks
Corvus pill shows promise in early-stage eczema trial - statnews.com
Bond Watch: Should I buy Nektar Therapeutics stock nowJuly 2025 Technicals & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aug Fed Impact: Should I buy Nektar Therapeutics stock nowMarket Performance Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Nektar Therapeutics Stock Defies Short Sellers with Sharp Rally - AD HOC NEWS
Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation - MSN
Short Interest in Nektar Therapeutics (NASDAQ:NKTR) Rises By 52.3% - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Trading Up 6.9%Still a Buy? - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Stock Price Down 6.7%What's Next? - MarketBeat
History Review: Is Nektar Therapeutics stock a value trapTrade Entry Summary & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Why the JP Morgan conference is important — but not make-or-break - statnews.com
BTIG maintains Nektar Therapeutics (NKTR) buy recommendation - MSN
Ignore Nektar Therapeutics stock in 2026 and load up on this one instead - MSN
Will Nektar Therapeutics (ITH0) stock outperform energy sector in 2025Trade Performance Summary & Step-by-Step Trade Execution Guides - ulpravda.ru
Nektar Therapeutics (NKTR) price target increased by 14.31% to 109.43 - MSN
Q1 EPS Estimate for Nektar Therapeutics Raised by Analyst - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200 Day Moving AverageHere's What Happened - MarketBeat
Here's why Nektar Therapeutics (NKTR) is a great momentum stock to buy - MSN
Nektar leaps a third on abuse-deterrent analgesic data - The Pharma Letter
Why Nektar Therapeutics stock remains on watchlists2025 Macro Impact & Advanced Swing Trade Entry Alerts - ulpravda.ru
Can Nektar Therapeutics stock sustain institutional interestJuly 2025 Earnings & Accurate Intraday Trading Signals - ulpravda.ru
Why analysts remain bullish on Nektar Therapeutics stockTrend Reversal & Weekly High Return Stock Forecasts - ulpravda.ru
Is Nektar Therapeutics stock a dividend growth opportunity2025 Trade Ideas & Precise Trade Entry Recommendations - ulpravda.ru
Is Nektar Therapeutics stock a buy in volatile marketsJuly 2025 Market Mood & High Accuracy Trade Alerts - ulpravda.ru
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Nektar Therapeutics Shares Rise After Positive Asthma Data in Atopic Dermatitis Patients - MSN
Nektar promotions promised to drive growth of I-O pipeline - The Pharma Letter
Portfolio Shifts: Why Nektar Therapeutics ITH0 stock trades below fair valueJuly 2025 Trends & Expert Approved Trade Ideas - moha.gov.vn
Nektar TherapeuticsCommon Stock (NQ: NKTR - FinancialContent
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks - Yahoo Finance
Nektar Therapeutics Too Risky? This Biotech Stock Offers a Safer Bet - NAI500
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - AOL.com
New anxiety medications are in the pipeline for 2026 - AOL.com
FDA Leadership Stability Urged as Rare Disease Drug Approval Policies Expected to Show Results by 2026 - geneonline.com
Nektar Therapeutics: Can a Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
What drives Nektar Therapeutics stock priceFinancial Sector Performance & Free Unlock Portfolio Growth - earlytimes.in
How Nektar Therapeutics stock reacts to global recession fearsGrowth vs. Value Investing & Optimize Entry & Exit With Smart Signals - bollywoodhelpline.com
Drugs to Watch in 2026 - Dermatology Times
Nektar Therapeutics Stock Analysis and ForecastStock Screening Results & Outstanding Return Portfolio - earlytimes.in
Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR - MarketBeat
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.57%
자본화:
|
볼륨(24시간):